10:53:43 EST Fri 08 Nov 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:EOLS - EVOLUS INC - https://investors.evolus.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
EOLS - Q0.113.77·13.830.113.83-0.46-3.2241.23,2081,99314.28  14.35  13.7217.82  7.7410:32:44Nov 0615 min RT 2¢

Recent Trades - Last 10 of 1993
Time ETExPriceChangeVolume
10:32:44Q13.7892-0.5008100
10:32:34Q13.7603-0.529714
10:32:32Q13.7981-0.491918
10:32:24Q13.83-0.463
10:32:24Q13.83-0.46500
10:32:24Q13.83-0.4625
10:32:23Q13.80-0.4923
10:32:09Q13.8028-0.48721
10:32:01Q13.80-0.4947
10:31:58Q13.80-0.49100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-11-06 16:05U:EOLSNews ReleaseEvolus Reports Third Quarter 2024 Results
2024-11-01 08:00U:EOLSNews ReleaseEvolus to Participate in Stifel 2024 Healthcare Conference
2024-10-31 14:02U:EOLSNews ReleaseEvolus Announces EU Approval of Estyme(TM) Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
2024-10-29 08:00U:EOLSNews ReleaseEvolus Rewards(TM) Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
2024-10-23 08:00U:EOLSNews ReleaseEvolus to Report Third Quarter Financial Results on November 6, 2024
2024-10-11 22:53U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-27 21:00U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-06 08:00U:EOLSNews ReleaseEvolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
2024-08-09 16:30U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-07-31 16:05U:EOLSNews ReleaseEvolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
2024-07-31 08:00U:EOLSNews ReleaseEvolus to Hold Investor Day on September 12, 2024
2024-07-30 08:00U:EOLSNews ReleaseEvolus Expands Global Footprint with Introduction of Nuceiva(TM) (botulinum toxin type A) in Australia
2024-07-25 08:00U:EOLSNews ReleaseEvolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
2024-07-17 08:00U:EOLSNews ReleaseEvolus to Report Second Quarter Financial Results on July 31, 2024
2024-07-01 08:00U:EOLSNews ReleaseEvolus Announces Appointment of Albert G. White III to Board of Directors
2024-06-24 08:00U:EOLSNews ReleaseEvolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse(TM) Dermal Filler Products
2024-06-12 08:00U:EOLSNews ReleaseEvolus Broadens International Presence with Launch of Nuceiva(TM) (botulinum toxin type A) in Spain
2024-06-07 17:00U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-20 08:30U:EOLSNews ReleaseEvolus Announces Positive Data from Pivotal Trial for First Two Evolysse(TM) Dermal Filler Products at 2024 SCALE Meeting
2024-05-10 18:55U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)